Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 17/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5216303 | 0.99 | CNR2 (0.68) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL5080770 | 0.92 | CNR2 (0.71) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL5213807 | 0.89 | CNR2 (0.54) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL5138678 | 0.87 | CNR2 (0.54) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL5247475 | 0.87 | CNR2 (0.57) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL5214866 | 0.86 | CNR2 (0.55) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL5212342 | 0.85 | CNR2 (0.59) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL4479173 | 0.84 | CNR2 (0.72) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL5214314 | 0.83 | CNR2 (0.75) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL5216408 | 0.83 | CNR2 (0.75) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565442-B1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2007-11-14 | — | — | EP | claimed |
| EP-1565442-B1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2007-11-14 | — | — | EP | disclosed |
| US-20060240048-A1 | Pyridine derivatives as cb2 receptor modulators | GLAXO GROUP LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060240048-A1 | Pyridine derivatives as cb2 receptor modulators | CNR2, CNR1, TRPV1 | CNR2 1/4885CYP3A4 1047/4885CYP2C9 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.